Use: Labeled indications
- INDICATIONS AND USAGE: Intraocular use for obtaining miosis during surgery.
Full indications and usage US FDA label
INDICATIONS AND USAGE: Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.
Contraindications
CONTRAINDICATIONS: Should not be used in those persons showing hypersensitivity to any of the components of this preparation.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION: Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use: Safety and efficacy in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Intraocular solution: 0.1 mg/mL
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Carbachol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
MiostatCarbachol | 0.1 mg/mL (0.01%) Intraocular SolutionUSP Type 1 Glass Vial with Rubber Stopper and Aluminum Seal x 1.5 ml (Box of 12's) | Rx | Alcon Research, LLCUSA | Importer: Alcon Laboratories (Phils.), Inc. | DR-XY7728 | Mar 29, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS: For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease. The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS: Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported. Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol.
The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) 0.01% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to MIOSTAT, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy: There are no adequate and well-controlled studies in pregnant women. MIOSTAT* (carbachol intraocular solution, USP) 0.01% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers: It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY: Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure (IOP). The exact mechanism by which carbachol lowers IOP is not precisely known.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Carbachol |
| PNF listing | Intraocular Solution: 0.01%, 1.5 mL vial |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. MIOSTAT · Alcon Laboratories, Inc. [US FDA-approved label, version 12, February 10, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f28d7a56-e079-4a8b-ad81-9a97c780de67
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .